NovoCure Limited
NVCR
$17.24
$0.392.32%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 674.41M | 655.35M | 642.27M | 630.16M | 621.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 674.41M | 655.35M | 642.27M | 630.16M | 621.71M |
| Cost of Revenue | 165.58M | 165.17M | 157.18M | 147.83M | 141.01M |
| Gross Profit | 508.84M | 490.18M | 485.09M | 482.34M | 480.70M |
| SG&A Expenses | 459.88M | 413.93M | 441.97M | 437.43M | 430.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 854.56M | 803.64M | 813.72M | 797.69M | 783.30M |
| Operating Income | -180.15M | -148.29M | -171.45M | -167.53M | -161.58M |
| Income Before Tax | -175.21M | -136.25M | -150.50M | -142.07M | -129.82M |
| Income Tax Expenses | -2.17M | -23.00K | 27.15M | 28.89M | 34.37M |
| Earnings from Continuing Operations | -173.05 | -136.23 | -177.65 | -170.95 | -164.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.05M | -136.23M | -177.65M | -170.95M | -164.19M |
| EBIT | -180.15M | -148.29M | -171.45M | -167.53M | -161.58M |
| EBITDA | -166.22M | -135.16M | -159.29M | -156.56M | -151.21M |
| EPS Basic | -1.53 | -1.22 | -1.61 | -1.56 | -1.51 |
| Normalized Basic EPS | -1.10 | -0.88 | -0.99 | -0.94 | -0.89 |
| EPS Diluted | -1.53 | -1.22 | -1.61 | -1.56 | -1.51 |
| Normalized Diluted EPS | -1.10 | -0.88 | -0.99 | -0.94 | -0.89 |
| Average Basic Shares Outstanding | 449.87M | 446.01M | 442.24M | 438.58M | 434.70M |
| Average Diluted Shares Outstanding | 449.87M | 446.01M | 442.24M | 438.58M | 434.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |